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ABSTRACT 
The emerging Coronavirus Disease-19 (COVID-19) pandemic has had a global impact on all important aspects of our society. As it is known, SARS-
Cov-2 can withstand up to 72 h in adverse environmental conditions, which can aid its rapid spread. Woefully, an efficacious and approbated 
vaccine for the SARS-CoV-2 virus remains unavailable, which makes the problem more frightening and presently more complicated bestowing 
forlorn medical care. Nevertheless, global clinical research is studying several over-the-counter (OTC) drugs approved for other indications to 
confront coronavirus. Over the past decade, therapeutic nanoparticles have been regarded as a felicitous tool for the efficient and persnickety 
delivery of therapeutic groups (i.e., drugs, vaccines, siRNAs, and peptides) to the site of infection. They can adequately convey the drug encapsulated 
nanoparticle to a designated locus without instigating unsought effects. Besides, they acquiesce the use of non-invasive imaging methods to monitor 
the surface of the infection and the response to treatment. The formulated nanoparticle is apposite for intranasal drug delivery which is a 
meritorious method to deliver therapeutic moiety for viral diseases affecting the lungs. Applying nanoparticles via intranasal route surmounted 
several demerits of mucosal administration like circumventing enzymatic degradation of the therapeutic moiety, upgrading and prolonging the 
action of the drug, etc., and can thus corroborate as an exceptional strategy to encounter respiratory viruses like coronavirus. In this article, we 
illuminate the promising role of nanoparticles as effective carriers of therapeutic or immunomodulatory agents to help combat COVID-19. 
The search criteria used were Pubmed, Medscape, Google scholar, etc and the keywords are coronavirus, nanoformulations, nanoparticles, drug 
delivery, intranasal delivery, etc. The articles range from 2012 to 2020. 
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INTRODUCTION 
Early the beginning of 2020, due to the continuing eruption of a novel 
Severe Acute Respiratory Syndrome, Coronavirus 2 (SARS-CoV-2), the 
global healthcare sector is undergoing a potentially hazardous 
condition. The World Health Organization (WHO) fired the sirens on 
30 January 2020 against a rapidly disseminating infectious disease 
initiated by the newly discovered SARS-CoV-2 and stated the condition 
as Public Health Emergency of International Concern [1]. WHO named 
this disease COVID 19 on 10th February 2020. COVID-19 stands for 
COrona VIrus Disease 2019 as it was first reported on 31st December 
2019 in Wuhan, China at the WHO Country Office as an unknown case 
of pneumonia. On 11th March 2020, it was declared a pandemic [2]. 
Coronavirus emerged in 2003 in China which was an epidemic that 
resulted in SARS and later in 2012 in Saudi Arabia it led to Middle East 
Respiratory Syndrome (MERS). This new virus, compared to the SARS-
CoV in 2002 is much more virulent and pestilent and has spread 
rapidly worldwide. Transmission of SARS-CoV-2 from person to 
person is approximated to take place mainly through breathing 
droplets developed as a result of sneezing, coughing, and conversation 
and this is largely comparable to the spread of influenza. Transmission 
can, however, occur when a person infected with or without signs is 
near a normal person [3]. Also recently WHO has found COVID-19 to 
be an air-borne disease. The common types of symptoms, emergency 
conditions, and the associated complications of coronavirus infection 
are shown in table 1. 
 
Table 1: Clinical manifestations of COVID-19 
Clinical manifestations 









-Loss Of Smell 









-Blue Lips And Face 
-Persistent Chest Pain 
-Inability To Stay Awake  
-Confusion 
-Pneumonia 
-Acute Kidney Injury 







Patients with COVID-19 mainly develop cardiovascular 
disease/hemodynamics or breathing problems. Studies revealed that 
patients with underlying diseases such as neutrophilia, organ failure, 
coagulation dysfunction, hypertension, lung disease, diabetes, chronic 
respiratory illness, and heart disorders may be at greater mortality 
risk when compared to other patients [4]. Age is also a significant 
factor since patients above 60 and children below 10 y of age are more 
prone to get infected as their immunity has been weakened or not fully 
developed. While considering the mortality rate to date, it has been 
found that males have more death rate than females [5]. Various 
diagnostic tests involved in screening COVID-19 include RT-PCR 
(Reverse Trancriptase Polymerase Chain Reaction), nucleic acid tests, 
antibody testing, and sequencing of genomes. Even though at present 
there no definite management for COVID-19, quite a lot of drugs 
permitted for other indications have been explored in clinical studies. 
These treatments rely on the drugs that prevent the virus from 
entering the host cell to shut out the virus from multiplying and 
infecting other cells, or potentially inhibiting protease activity 
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(antiviral drug ritonavir/lopinavir). Other promising treatments in 
clinical research, employ nucleoside analogs that aim at RNA-
dependent polymerase, which inhibits the production of viral RNA (i.e. 
Remdesivir), or directly affect the assembly of virions and buds, and 
modify the molecular crosstalk of SARS-CoV-2, while ultimately 
decreasing the generation and/or activation of pro-inflammatory 
cytokines anti-SARS-CoV-2 CD8+T cells (ie hydroxychloroquine). This 
article mainly focuses on the drug design strategies against COVID-19 
virus especially nanoparticle-based treatment which emphasis on 
intranasal administration.  
Structure of COVID-19 virus 
A study conducted by Prasad et al. in March 2020 revealed that the 
electron microscopy image of SARS-CoV-2 manifested the 
appearance of stalk-like protuberance that ends in round 
peplomeric assembly which is prototypical for a particle-like 
coronavirus [6]. Coronavirus is an enveloped virus with positive-
sense single-stranded RNA composed of 30,000-bases and has a 
mean diameter of approximately 125 nm (125 μm). The diameter of 
the envelope of the coronavirus particle is 85 nm and the length of 
the spike is 20 nm. They have a characteristic crown-like structure 
after which they are named. Coronaviruses are the largest among 
the known RNA virus and they belong to Coronaviridae and 
Nidovirales; family and order respectively [7]. There are 4 
genera/subgroups of coronaviruses:-alpha coronaviruses, beta 
coronaviruses, gamma coronaviruses, and delta coronaviruses. 
Darwinism study or evolutionary analysis discovered the gene 
sources of these subgroups. The gene sources of alpha coronaviruses 
and beta coronaviruses are rodents and bats while avian species are 
the gene sources of gamma and delta coronaviruses. SARS-CoV-2 
belongs to the beta subgroup of coronaviruses. Like other βCoVs, the 
SARS-CoV-2 genome contains two untranslated flanking regions and 
a long open sequence. The reading frame encodes a polyprotein. The 
SARS-CoV-2 genome sequence is the structural protein 5'replicase 
(orf1/ab) [S-E-M-N]-3 ', and the hemagglutinin esterase gene is 
missing which is the characteristics found in β-CoV type A. 
The genome of SARS-CoV-2 encodes four main structural proteins 
[spike (S), envelope (E), membrane (M), and Nucleocapsid (N)], 
approximately 16 non-structural proteins (nsp1-16), and 5 to 8 
other proteins. Protein S binds to the virus, fuses, enters, and 
induces transmission. The spike on the surface of the coronavirus is 
a homotrimer of S protein, consisting of 2 subunits, the S1 subunit, 
and the S2 subunit. The N-terminal and C-terminal include the S1 
subunit and the S2 subunits which are responsible for viral receptor 
binding. The homotrimeric protein S is a class I fusion protein that 
can mediate binding to receptors and fusion of membranes of the 
virus and the host cells. The head of the spike forms the S1 subunit 
and possesses a receptor-binding domain (RBD) and N-terminal 
domain (NTD). The S2 subunit forms the stem that holds the spike in 
the viral envelope and allows fusion during the activation of the 
protease enzyme. E and M proteins are the fundamental proteins 
required for the formation of viral envelopes and the preservation of 
their structural configuration. The viral envelope is made of a lipid 
bilayer, in which the structural proteins like a membrane (M), 
envelope (E), and spike (S) are anchored. The ratio E: S: M in the 
bilayer of lipids is about 1:20:300. Coronavirus particles have an 
average of 74 spikes at the surface [8, 9]. The genome has 
a methylated cap at the 5’ end and a polyadenylated tail at the 3’ 
end. The organization of the genomic material of coronavirus is 5′-
leader-UTR-replicase (ORF1ab)-spike (S)-envelope (E)-membrane 
(M)-nucleocapsid (N)-3′UTR-poly (A) tail. Surprisingly, orf3b 
encodes for a new protein which is short. Additionally, the new orf8 
can encode a secreted protein having an α spiral, then a six-chain 
beta plate. Using direct RNA sequencing and synthetic sequencing, 
Kim provided high-resolution maps of the transcriptome and the 
SARS-CoV-2 epitope transcriptome. In addition to viral genomic RNA 
and 9 canonical subgenomic RNAs, SARS-CoV-2 will also produce 
transcripts encoding unknown ORFs with fusions, deletions, and/or 
turn code. The researchers also established that there are about 41 
alteration sites in RNA in viral transcription, the commonest reason 
being AAGAA [10]. In a study conducted by Paraskevis et al., and 
Fahmi M et al., it was described as SARS CoV-2 can be the result of 
the accumulation of mutations in response to changes in selective 
stress, or of the fickling RNA polymerases that continue to exist by 
replicating neutral mutations [11, 12]. The diagrammatic 
representation of the structure and genomic composition of the 
SARS CoV virus is shown in fig. 1. 
 
 
Fig. 1: Structure and genomic composition of SARS-CoV-2 virus 
 
Pathophysiological mechanisms associated with SARS—COV2 
infection 
Covid 19 viruses are positively stranded enveloped nucleocapsid 
retroviruses. The synthesis of polyprotein 1a/1ab (pp1a/pp1ab) is 
recognized in the host beginning with the viral RNA. Once the virus-
related genome of RNA is released into the cytosol, the RNA 
undergoes uncoating to enable transcription of the viral genome 
RNAs and genomic replication. The process of transcription occurs 
through the RCT complex known as the Replication transcription 
complex produced by the synthesis of subgenomic sequences of 
RNA. The termination process of transcription occurs in the 
regulatory transcription sequences which are housed between the 
open reading frames (ORF) that acts as the template for the viral 
genome mRNA assembly. About 6 ORFs are present in the atypical 
form of the genome of CoV [13]. 
The first step in the pathogenesis of COVID-19 infection is viral 
tropism. The presence of S protein is accountable for the access of 
the virus into the host cell and it occurs after attaching to the 
receptor of the cell. The angiotensin responsible for the conversion 
of enzyme 2 (ACE2) was considered as the cellular receptor of the 
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host for the spike glycoprotein SARS-CoV2 envelope. ACE2 is mainly 
found in blood vessels, kidneys, heart, gastrointestinal tract, and 
particularly the epithelial cells present in the pulmonary system are 
susceptible to infection. In the pulmonary system, the ACE2 are 
identified in the bronchus, alveoli, trachea, etc. Hoffmann, in a study, 
established that the virus makes use of the ACE2 receptor for its 
entry and also TMPRSS2, a serine protease used for priming of S 
protein [14]. Following the sequencing of a single cell, Meng 
discovered that in type II alveolar cells (AT2) there was a presence 
of increased genes linked with endocytosis indicating that the 
process of endocytosis allows the entry of the virus into the host cell. 
In the AT2 cells, the SARS CoV virus causes damage to alveoli as well 
as augment the surface tension in the alveoli leading to dyspnea 
[15]. Chen identified that the expression of ACE2 in the pulmonary 
system increased exponentially by age. Thus, a significant viral count 
in older patients may not only be linked with less immunity but also 
with strong ACE2 receptor expression. Therefore, these data 
concurrently suggest the increased level of serious disease in older 
SARS-CoV-2 patients. Following viral tropism, the next step in covid 
pathogenesis is the entry portal. ACE2 expression in salivary glands 
was larger when compared to the pulmonary system, inferring that 
salivary glands could be a possible target for SARS-CoV-2. Hui 
noticed that the epithelium of the conjunctiva and the conducting 
airways seem to be a plausible entrance for SARS-CoV-2 infection 
with the help of in vitro and ex vivo studies. The major targets for 
the virus are mucus cells, ciliated and club cells of the epithelium of 
bronchioles, conjunctival mucosa, and type I pneumocyte cells [16].  
The next step is enhanced expression of receptors in which a study 
conducted by Ziegler revealed that the production of interferon 
stimulates the ACE2 expression in the pulmonary tissues and nasal 
epithelium. This led to the conclusion that the pathway of interferon 
necessary to protect the host against virus leads to increased infection 
[17]. The next step is the infection occurring to immune cells. Wan 
demonstrated that T cells were infected with SARS CoV-2 and infection 
occurred through receptor-associated fusion which was facilitated by 
S protein [18]. Acute respiratory distress syndrome (ARDS) occurs 
which results in cytokines and chemokines upregulation leading to 
another syndrome known as cytokines release syndrome. The 
syndrome pattern is quite comparable to sHLH (secondary 
haemophagocytic lymphohistiocytosis). In most of COVID 19 affected 
people, a cytokine enhancement pattern similar to that of sHLH is 
observed. There is an increase in levels of cytokines like IL-1β, IL-6, IL-
7, IL-8, etc, TNF and other chemokines in COVID-19 suspected 
individuals [19]. The mechanism of virus entry into the host cell and 
types of drugs used to prevent the different steps involved in the 
pathogenesis is shown in the following fig. 2. 
 
 
Fig. 2: Pathogenesis involved in SARS CoV2 infection and the drugs targeted to inhibit each step in the pathogenesis 
 
Conventional treatment for the management of COVID-19 
To achieve proper management of COVID-19, no clear and exact 
treatment with antiviral agents has been identified yet. About 
patients diagnosed with COVID-19, it was proposed that adequate 
symptomatic treatment and supportive cautions be pursued. The 
supportive measures include respiratory and cardiovascular 
support and helps to eliminate side effects and complications rather 
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than killing the virus [20]. Respiratory support seems to be the 
primary step taken care of by the healthcare team and the various 
respiratory support systems included are non-invasive positive 
pressure ventilation (NPVV), conventionally done oxygen therapies, 
and the use of high flow nasal cannula. An epidemiological study 
conducted on a group of COVID-19 affected patients showed that 
NPVV appears to be the commonly used respiratory support system 
for the treatment of acute respiratory failure. For patients suffering 
from respiratory failure with early COVID-19 stage, the use of NPVV 
is suggested for about 1 to 2 h and if the condition is still not 
improved, then intubation should be done [21]. 
Six clinical trials were recorded in both the Chinese Clinical Trial 
Registry and the International Clinical Trials to assess the 
effectiveness or safety of the focused medicines for COVID-19 
prognosis. For finding out an effective treatment method for COVID-
19, it is of prime importance to understand how the virus acts [22]. By 
using machine learning software, Richardson P. et al. proposed that 
AAK1 (AP2-associated protein kinase 1) linked drugs could disable the 
virus from reaching the target cells. Conversely, large levels of such 
inhibitors, such as chemotherapeutic drugs like Erlotinib and Sunitinib 
are needed, which may result in serious adverse effects [23]. Another 
drug Baricitinb belonging to the class Janus kinase (JAK) inhibitor can 
attach to cyclin G-linked kinase, another regulator of endocytosis, and 
can cause AAK1 inhibition thereby constraining the viral entry into the 
cell. Certain remarkable COVID-19 inhibitors comprise inhibitors of 
HIV protease, such as Lopinavir and Ritonavir, which counteract SARS 
and MERS 3-chymotrypsin-like proteases [24]. To determine the 
performance of these antiviral medications, several clinical 
experiments were instituted. Phase IV clinical trial study was 
demonstrated to test the success of antiviral drugs Lopinavir and 
Ritonavir in the therapy of viral pneumonia in COVID-19 affected 
individuals. A clinical study is scheduled to examine the safety profile 
and efficiency of Baricitinib with Lopinavir/ritonavir (together with 
other two additional medicines) in the treatment of serious COVID-19 
infection in hospitalized individuals [25]. Also in a clinical 
uncontrolled trial, 12 patients with pneumonia having mild COVID-19 
were provided with baricitinib at a dose of 4 mg/day through oral 
route along with the combination of lopinavir and ritonavir, and no 
clinical adverse effects were reported with augmented benefits in 
respiratory and clinical outcomes [26]. 
Other proposed alternative therapies include Remdesivir (RDV), an 
analog in the nucleoside group that can target specific RNA-
dependent polymerase preventing the production of viral RNA in a 
large variety of viruses like the coronavirus [27]. Holshue M. et al. 
described healthy retrieval of a patient infected with SARS-CoV-2 
who received Remdesivir through the IV route had a healthy 
recovery without adverse outcomes. Umefenovir, Favipiravir, 
Oseltamivir are other antiviral agents used alone or in combination 
with other drugs for treating coronavirus [28]. Chloroquine (CQ) or 
the use of hydroxy-chloroquine (HCQ) has been of significant 
importance in treating the infection with the COVID-19 virus. 
Guidelines that include the use of Hydroxy-Chloroquine 
strengthened by Azithromycin indicated supporting results for 
reliable COVID-19 treatment. But, the mechanism of action of 
chloroquine by which it can effectively treat the virus remains 
doubtful. Possibly, it acts by preventing the SARS virus from fusion 
with the host cells by lysosomal acidification and obstructs 
cathepsins that need smaller pH for breaking spike protein of SARS 
CoV-2 [29]. CQ has the potential to decrease proinflammatory 
cytokine production and also stimulates the action of anti-SARSCoV-
2 CD8+cells. The combination of CQ and Remdesivir has been 
recognized as the treatment method for pregnant women with 
COVID-19 [30]. Remdesivir remains harmless in pregnant women 
while CQ and its metabolites cross the placenta but remains safe 
during all trimesters without any greater risk for perinatal negative 
events. The drug is used in women who are pregnant necessities to 
be based on conclusive evidence [31]. ARDS is one of the primary 
complications of COVID-19 which can lead to severe problems 
including mortality. Various therapeutic strategies involved in 
treating ARDS comprise anti-inflammatory drugs like steroids, anti-
proteases, anti-oxidants, etc., and other agents like anticoagulants, 
diuretics, beta-2-agonists, etc. Diverse therapies are emanating to 
treat this complication and include macrolides, insulin, anti-
interleukin-8, ACE inhibitors, colony-stimulating factors, etc [32, 33]. 
Some experts have proposed the use of heparin in COVID-19 
because of the increased occurrence of venous thromboembolism 
and intravascular coagulation. The success of this intervention, 
however, remains to be confirmed [34]. 
Recently, dexamethasone was proved as the first drug to indicate the 
survival improvement in patients suffering from COVID-19. The 
treatment with this steroid was verified on patients using a 
randomized trial with a dose of 6 mg once daily through oral or IV 
route. It was shown that the use of dexamethasone minimized death 
by around 35% in ventilatory patients and by 20% in patients who 
received oxygen supplementation. Supportive measures currently 
under practice include the use of antibiotic Azithromycin in 
combination with hydroxychloroquine which showed better results 
compared with Azithromycin alone [35]. Other supportive measures 
include the use of Vitamin C, corticosteroids, and 
immunosuppressive agents like sirolimus which had shown to 
inhibit the activity of MERS-coronavirus. Tocilizumab, a monoclonal 
antibody was found to be effective in severely coronavirus-affected 
individuals resulting in the recovery of patients in a study issued in 
April this year. Convalescent plasma has gained good appreciation in 
treating people with this novel virus. In this method, blood is drawn 
from patients who had recovered from the infection and the 
obtained plasma is administered to the infected patient. The use of 
this plasma helps the infected patient to augment their capacity to 
attack the virus [36]. Some of the adjunctive therapies involved in 
treating SARS-CoV 2 are shown in table 2.  
 
Table 2: Few of the adjunct therapies used for treating COVID-19 
 S. No. Category Drug Dose Benefits References 
1. Corticosteroids Dexamethasone 6 mg oral per day Reduce the inflammatory response of 




Tocilizumab 400 mg Enhancement in clinical outcome with 
enhanced respiratory status with 




Immunoglobulin 0.3 to 0.5g/kg/day IV Helps in reducing mortality associated 






and nitric oxide 
Maximum of 50ng/kg for 
epoprostenol and 30 ppm on first 
day, 20 ppm on second day and 
about 10 ppm for third day in case 
of nitric oxide. 
They can significantly reduce arterial 
pressure in the pulmonary system and 
can augment oxygenation. 
[36] 
5. Vitamins Vitamin C 1500 mg Aids in the growth of T lymphocytes and 
natural killer cells and thus leads to 
developed immune responses. Also 
helps in reducing the generation of 
reactive oxygen species  
[33, 34] 
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Amid these emerging possible treatments, however, the death rate of 
patients diagnosed with this new coronavirus continues to rise 
alarmingly. Consequently, attempts should focus in parallel on an 
alternative proposal for successful therapy whilst minimizing adverse 
effects. Current treatment has limitations such as reversing of 
infectivity contributing to poor inflammatory response and limited or 
reduced immunogenicity. Higher doses of the therapeutic agents are 
necessary to provide optimum benefits which can lead to serious 
adverse outcomes. The unremitting growth of novel and mutated 
strains of coronavirus limits the benefits of the proposed treatments 
with antiviral agents and urges the application of specific antiviral 
agents or other innovative methods for these new mutated genes [37]. 
Existing old therapy for targeting coronavirus infection 
The theory of reuse of drugs justifies attention in the treatment of 
the COVID-19 pandemic due to its exceptionally great infection 
pressure and the urgent necessity to satisfy unmet medical needs. 
The reused drugs are very useful because they can avoid preclinical 
research related to drug research and quickly benefit patients [38]. 
Guo concised the relevance of regenerative medicine in COVID-19 
therapy and other related viral diseases [39]. Wang et al. assessed 
medications approved by FDA, comprising ribavirin, nitazoxanide, 
penciclovir, chloroquine (CQ), narfalimus, and other two recognized 
broad-spectrum antiviral medications, Lundvir (RDV, GS-5734) and 
Faviprevir (T-705) is a 2019 nCoV clinical isolate in a cell culture 
infection model. The authors found that the two compounds CQ 
(EC50 value = 1.13 μmol/l; CC50>100 μmol/l, SI>88.50) and RDV 
(EC50 = 0.77 μmol/l; CC50>100 μmol/l; SI>129.87) at low 
micromolar concentrations strongly block viral infections and show 
a large index of selectivity. RDV has been observed to be functional 
against multiple viruses and is currently being evaluated in clinical 
studies to assess its effectiveness to fight the infection from Ebola 
virus. The research provides further information about the use of this 
adenosine analog precursor to battle COVID-19 infection. Apart from 
this, CQ is recognized for its antimalarial infection and its anti-
inflammatory effects [40]. Attributes additionally, CQ is accepted for 
the therapy of autoimmune diseases like lupus erythematosus and 
rheumatoid arthritis. And recently it was found that CQ has unveiled to 
subdue infections of various viruses including SARS coronavirus, 
MERS coronavirus, EBOV, chikungunya virus, influenza A virus, 
dengue virus, human immunodeficiency virus, fever virus 
hemorrhagic from Crimea Congo, West Nile virus, and hepatitis A virus 
[41]. Savarino et al. confirmed that the drug CQ could effectively pass 
into cells and accumulate in acidic compartments, like endosomes, 
suicidal bags, and vesicles of the anti-Golgi network [42]. 
Therefore, they increase pH and many viruses require acid 
endocytosis at certain phases of replication, like viral membrane 
removal and cell entry through membrane fusion. Consequently, the 
well-described CQ action needs a lot of consideration [43]. Tony 
provided the most likely pharmacological action for CQ against 
SARS-CoV-2, namely, inhibition of binding of phosphatidylinositol to 
clathrin assembly protein (PICALM), which hinders the endocytosis 
mediated ingestion of SARS-CoV-2 cells [44]. Gao and others 
reported that in a multicenter clinical study in China, chloroquine 
phosphate was very efficient and secure for pneumonia linked with 
COVID-19. Due to its activity against SARS-CoV-2, hydroxychloroquine 
(HCQ), a hydroxylated derivative of CQ, has also been recently 
reported [45]. Zhou et al. proposed that HCQ can reduce the serious 
progress of COVID-19, subdue cytokine storm by inhibiting activation 
of T cell, and has the benefit of clinical safety, particularly appropriate 
for females who are pregnant [46]. Gautret et al., efficaciously 
established the synergistic effect of hydroxycholine and the antibiotic 
azithromycin for about 20 cases of COVID-19, with detection of 
effective virus clearance. Similarly, Xu and others also testified the 
usefulness of the broad-spectrum antiviral drug Nilosamide on COVID-
19. This work is also an important instance of drug reuse, as it extends 
its possibility to clinical trials [47]. Fan et al. made use of the pangolin 
coronavirus GX_P2V as a viable model to assess the value of drugs 
recovered in nCoV treatment in 2019. This study showed that 
cefuroxime (CEP), selamectin, and mefloquine hydrochloride showed 
complete prevention of cytopathic events in cell cultures of 10 μmol/l, 
of which CEP had the strongest inhibitory effect on GX_P2V infection. 
The concentration is 50% of the maximum effect [EC50 [0.98 μmol/l] 
[48]. Hui et al. recommended a combination of rifaxivir, ritonavir or 
lopinavir, lopinavir or ritonavir and interferon-beta, for patients with 
recovery plasma nCoV pneumonia and monoclonal antibody in 2019. 
Cao et al. noted the controversial results in the treatment with 
lopinavir-ritonavir was found to be in no way superior to normal 
treatment [49]. Wang et al. conveyed that patients who received 
antiviral therapy for symptoms related to pneumonia, including 
lopinavir/ritonavir. The treatment also significantly reduced the viral 
load of the β-coronavirus [50]. Russel and others reported that 
corticosteroids are ineffective in treating nCoV lung injury in 2019. All 
of these observations suggest extensive research to understand the 
effect of conventional antiviral drugs on COVID-19 [51]. Liu et al. 
observed that, as shown in in vitro
Sang et al. confirmed the hypothesis of using HIV-1 protease inhibitors 
as anti-SARS drugs by attacking SARS-Co-V 3CLpro. The author used 
six approved anti-HIV-1 medications to study their binding interaction 
between 3CLpro. Molecular coupling and MM-PBSA binding free 
energy calculations show that, of all inhibitors, Darunavir has the 
greatest binding affinity for SARS-Co-V-2 and SARS-Co-V 3CLpro, 
specifying that it can be converted into an anti-COVID-19 drug [53]. 
Chen and others used a 3CL (pro) molecular model for virtual 
screening, noting that the antiviral agent's ledipasvir or velpatasvir are 
particularly striking therapeutic agents, having double inhibitory 
effects on two viral enzymes with insignificant adverse events. 
Antiviral effects present with phytochemicals must also attract a great 
deal of attention [54]. Shaghaghi testified on the usefulness of 
terpenoids as fewer hazard drugs through molecular coupling 
experiments on the new protease COVID-19 [55]. Elfiky recommends 
Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as effective alternative 
medications for HCoV disease, which is a worthy example of the reuse 
of drugs [56]. Baron et al. stated teicoplanin, an antimicrobial agent 
employed in the management of 
 studies, anticoagulant dipyridamole 
(DIP) inhibited HCoV-19 replication at an EC50 of 100 nM. The 
authors carefully chose DIP by examining the drug approved by the 
FDA and determined that patients infected with HCoV-19 may gain 
improvement from DIP adjuvant therapy by dropping multiplication of 
virus, inhibiting thrombophilia, and improving immune repair [52]. 
staph
Nanoparticles to confront respiratory virus and treatment 
modalities 
 infections, can be used as an 
alternative medicine for patients affected by SARS-Cov-2. This 
observation must be confirmed by animal studies because it is 
effective against preceding coronaviruses [57]. 
The implementation of NPs in the field of medicine is very significant 
in the establishment of innovative theranostic and diagnostic 
approaches for COVID-19 management. Nano platform suggests 
innovative answers to a wide range of aspects linked to the 
diagnosis, prevention, and management of the COVID-19 pandemic. 
Since the virus particle causing COVID-19 has a width of 
approximately 125 nanometres, nanoparticles with this identical 
width range can be very useful to identify and incapacitate this 
unique coronavirus through several interventions [58]. The low 
toxicity, smaller size, charge, and chemical alteration of the 
nanoparticles enable these materials to resolve the numerous 
constraints that hinder their passage through several methods of 
administration [59]. The introduction of treatment interventions 
centered on nanoparticles (NPs) will overcome the drawbacks of 
current therapy with features such as size, shape regulation, and 
surface modification that eventually result in high immunogenicity 
and increased presentation of antigen. The implementation of 
nanoparticles as carriers for drug delivery can enhance the targeting 
of drugs to desired regions thus reducing the amount of dose 
needed, eliminating undesirable adverse effects, and improving 
compliance of patients [60]. Integration of nanoparticles with the 
therapeutic agent protects the molecule against enzymatic 
degradation, and thus the concentration of the therapeutic agent is 
many times higher than the expected concentration at the target 
site. NPs offer an excellent drug delivery with the capability to cross 
the barriers and carefully release drugs to the suitable target [61]. 
These particles also can improve the therapeutic efficacy of antiviral 
drugs as well as augment their pharmacokinetic profile of the drug 
[62]. The most important nanoparticles used for combating the 
COVID-19 pandemic are polymeric nanoparticles, liposomes, (both 
Nair et al. 
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of which belong to organic NPs), gold NPs belonging to inorganic 
NPs, nanoparticles of virus-like and self-assembling proteins, and 
peptide-based NPs [63]. The commonly used nanoparticles with 
their classification are described in fig. 3. 
 
 
Fig. 3: Classification of nanoparticles based on their nature 
 
Polymeric nanoparticles (PNPs)  
Polymeric Nanoparticles prove to be excellent carriers for drug 
delivery due to their biocompatible nature, and the likelihood of 
altering their functions and characteristics for specific delivery of 
drug molecules [64]. PLGA (Poly-lactic-co-glycolic acid) is the 
frequently used polymer in this category with biodegradable and 
biocompatible features. These types of NPs can be produced by the 
addition of numerous monomeric molecules into different forms like 
3 dimensional, linear, branched forms, etc [65]. The natural or 
synthetic type of PNPs are used for carriers of drugs or genes and 
can load siRNA (small interfering RNAs) and these are described as 
effective molecules to target the virus and have the ability to attack 
mutations in the virus. Different studies have revealed the 
effectiveness of siRNA in preventing replication of the virus, 
especially in Hepatitis C. The specificity and selectivity of this 
molecule are the reason for the success of the site-specific treatment 
approach. The delivery of this RNA without any protective cover 
makes it more susceptible to enzymatic degradation along with 
subsequent effects like instability, toxicity, clearance by the 
reticuloendothelial system and kidneys. Thus, siRNA can be tagged 
with NPs, especially polymeric NPs either with chitosan or with 
polyethyleneimine to deliver this delicate molecule to the target site. 
Chitosan-type NPs have confirmed their potential in providing 
immunity against various viral infections and were also examined 
for incorporation into different types of vaccines like the HBV 
vaccine [66]. 
Liposomes  
Liposomes are lipid-based nanoparticles having numerous 
applications in the biomedical field due to their biocompatible 
nature. Liposomes are characterized by having a spherical shape 
with an outer bilayer consisting of phospholipids and an inner core 
that is hydrophilic so that it can load hydrophilic therapeutic moiety 
[67]. These nanoparticles offer advantages like they can effectively 
enclose the therapeutic moiety and can undergo simple alterations 
thus enhancing the biocompatibility and enabling easy drug delivery 
to the target site. Apart from PNPs, lipid nanoparticles also offer 
effective delivery of siRNA against numerous viral diseases. Diverse 
formulations of lipid nanoparticles like semi-solid particles, solid, or 
even liquid form were assessed for targeting viral infections. siRNA 
loaded with lipid nanoparticles are also targeted for treating MERS-
coronavirus [68]. The lipid-based nanoparticles guard siRNA from 
enzymatic degradation by the nuclease enzyme thus augmenting 
their distribution and enhancing the bioavailability of low soluble 
drugs and ensuring that the therapeutic agent reaches desired 
region [69]. 
Inorganic nanoparticles  
Inorganic nanoparticles gain attention in the biomedical field due to 
their capability to convey the nanoparticle to the specified target site 
and also permit stimuli-responsive properties, with biocompatibility 
and optical characteristics [70]. Although inorganic NPs are widely 
researched in clinical and preclinical settings in the identification, 
diagnosis, and treatment of various diseases they still raise issues 
about their effective medical applications regarding factors such as 
bio-compatibility and specificity. To resolve this, research teams are 
focusing on inorganic functionalization of the nanoparticles with 
different kinds of biocompatible constituents thus providing 
promising benefits of organic as well as inorganic nanoparticles 
[71]. Gold nanoparticles, being an inorganic nanoparticle offer a 
great advantage in the treatment of COVID-19. Along with gold 
nanoparticles, various other inorganic nanoparticles like silica 
nanoparticles, magnetic iron oxide, carbon nanotubes, and quantum 
dots were assessed as promising transporters of siRNA [72]. Gold 
NPs were emanated as impressive nanosystems and were evaluated 
for target-specific gene silencing and as a carrier of siRNA against 
neoplasm due to their incomparable biocompatibility, adaptable 
designs, and surface adjustments and thus lead to efficient 
distribution mechanisms [73]. Important research done by 
Loczechin A et al. revealed that carbon quantum dot conjugated 
ligands of boronic acid disturbed the function of the S protein of the 
coronavirus and significantly prevented the entry of the virus into 
the host cell. The addition of inorganic NPs to the cell culture 
medium confirmed that the rate of infection of the cells dropped 
dramatically during and before infection with coronavirus [74]. A 
significant inhibitory activity of the virus was identified at the phase 
of viral replication after the end of one cycle of viral life. This 
nanomedicine with outstanding water solubility is a potential 
candidate for attacking coronavirus as it can efficiently enter cellular 
components via endocytosis and intermingle with the protein of the 
virus thus inhibiting the replication process of the virus. 
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Nanoparticles made of silica propose safe and efficient therapeutic 
delivery mechanisms and may aid in formulating a vaccine for 
treating coronavirus [75]. Nanoparticles formulated with silica 
provide stable and biocompatible candidates to load DNA, 
RNA,siRNAs. The silica-based NP are conjugated with 
polyethyleneimine and can accurately deliver nucleic acids. This 
formulation shelters the nucleic acids from degradation by nuclease 
and once the nucleic acid is delivered to the cell, it results in the 
stimulation of the immune system causing humoral and cell-
mediated immunity [76]. The cell-mediated reaction will identify 
and destroy the cells infected with the virus and the antibodies 
produced from the humoral response can bind to the virus, 
impeding its ability to attach to the cell and rapidly eliminating it by 
phagocytic processes.  
Virus-like nanoparticles (VLNPs) and self-assembling protein  
VLNPs exist as spherical nanoforms composed of multiple 
components having a size range between 20 to 200 nm. They are the 
products of the self-assembly of viral capsid-derived proteins. These 
were implemented as desirable nanoparticles which do not consist 
of genomic elements but can appropriately impersonate the original 
virus based on its structure and epitope. This allows the 
nanoparticles to stand out to antigen-producing cells which can 
easily detect them and induce an immune response. VLNP can act as 
a vector in the transfer of human genes in which could be regarded 
as one of the brilliant methods for appropriately transporting a 
transgene to the mutated site to alter the expression of a gene or 
protein-encoding [77]. With the great improvements in vaccine 
research, massive attempts were concentrated on designing new 
vaccines using VLNP which can imitate the viruses. These NPs can 
also stop the degradation by enzymes when compared to the 
unprotected administration of viroids [78]. Self-assembling 
nanoparticles are an innovative form of nanomedicine generated 
from the monomeric proteins oligomerization reactions (with a 
diameter of approximately 20 to 100 nanometres). They are an 
excellent form of drug delivery wherein they can easily cross cell 
membranes and safely release drugs, nucleic acids, and genetic 
components into the nucleus of the cell [79]. These nanoparticles 
can not only act as drug carriers but can also activate the immune 
system thus carrying synergistic actions. Chen H. et al. [80] revealed 
that in an experiment of combining gold nanoparticles with the S 
protein of a virus causing infectious bronchitis; the stability was 
enhanced after VLNP was used. This also had substantial S protein 
retention when compared to virus-related antigens. Also, it was 
established that the use of VLNP caused higher levels of IgG because 
of improved gold NP drug delivery leading to enhanced cell uptake 
and strengthened fixation of complement. 
Peptide-based nanoparticles  
Nanoparticles made of peptides are a newly evolving multipurpose 
tool meant for medical applications and facilitates the management, 
prevention, and diagnosis of various diseases [81]. The covering of 
this NP with peptides or proteins enhances the stability of NPs 
biologically and can modify and control the accumulation of NP in 
tissue by allowing interaction with biomolecules and the cell 
structures of the host [82]. In a study done by Han Y and Kral P, it 
was revealed that peptide inhibitors taken out from the ACE2 gave 
encouraging results for inhibiting the SARS-CoV2. These inhibitors 
are produced from alpha-helices which are extracted from ACE2 and 
it was shown that the peptides of alpha-helices sustained their 
structure and enabled stable and definite binding to the viral 
structure. To facilitate multivalent binding to the receptors of the 
virus, different kinds of peptide moiety can be linked to the NP 
surface. Thus, the peptide-based NPs can deliver effective 
therapeutic assistance to attack the COVID-19 disease [83]. 
Nanoparticles formulated in supporting agents  
Presently, copper or silver salt conjugated with disinfectants are 
easily available as these nanomedicine-related products can 
incapacitate the SARS Cov-2, reduce opportunistic microbes and 
prevent viruses present on the surfaces [84]. Nanoparticles are also 
used to enhance the utility of air filters and can also minimize the 
spread of viruses. Nanotechnology is also applied in producing 
wound dressings because it can defend the viral infections and 
enhance the rate of healing speed [85]. Nanomaterials can minimize 
microbial biofilms resulting in a decreased opportunity for 
secondary microbial infectious diseases [86]. Thus they can augment 
the potency of antimicrobial drugs and thus resist secondary 
microbial infections. Nanotechnology makes use of nanofibers and 
other nanomaterials which can be integrated into respiratory masks 
enabling great filtration rates and breathing efficiency along with 
washing capability and antibacterial, antiviral properties [87]. ACE-2 
conjugated nanoparticles like quantum dots and nanoflowers are 
formulated in nose filters, masks, gloves, clothes, etc., and thus can 
block the entry of the virus into the host [88]. Recently, the 
demonstration was done on the use of a replaceable nanoporous 
membrane conjugated with silicon for its incorporation in N-95 
masks. This type of mask can overcome problems associated with 
normal N-95 masks like the possibility of the formation of cakes that 
occur due to the collection of particles on the membrane and thus 
inhibiting the further passage of additional particles. The porous 
membrane present on this is made of hydrophobic molecules and 
when the respiratory droplets come in contact with the mask, it gets 
rolled and slipped over the mask because of the high angle of 
inclination of the membrane when it is present on the mask [89]. 
Other applications under consideration are enhancement of 
detection kits since it is considered as one of the foremost 
requirements of the present approaches to face and tackle the 
spread of coronavirus [90].  
Intranasal delivery through nanocarriers  
The different types of nanoparticles loaded with drugs, vaccines, 
antibiotics, siRNA can be targeted to the desired region effectively 
via the intranasal route [91]. Intranasal drug delivery has already 
been evaluated against respiratory infections causing virus and 
coronaviruses. There are several benefits for drug delivery via a 
mucosal route which include guarding the drug against degradation 
by enzymes, prolonging the release and time of residence of the 
drug, enhancing the amount of loaded drug in the target region, 
guaranteeing the release of the drug along with adjuvants and 
stimulating the immune system [92]. Intranasal delivery of drugs is 
highly beneficial for infective diseases as most invading organisms 
commence their action at the mucosal surfaces. This therapy offers 
modest, cost-effective, and non-invasive delivery mechanisms [93]. 
The increased surface area and the abundance of the capillary bed 
offer rapid absorption of drug moiety. The nanoparticle-related 
factors that play an important role in enhancing intranasal drug 
delivery are size, the surface charge of the nanoparticle, 
characteristic features, etc [94]. A variety of studies have been 
carried out to determine the desired characteristics of nanoparticles 
for intranasal administration and have been tested recently [95]. For 
an ideal delivery of a drug through the pulmonary system, the 
nanoparticles should have a size of less than 100 to 200 nanometres 
to have an augmented immune response [96]. It is to be noted that 
most of the studies done to evaluate the benefits of using 
nanoparticles for intranasal delivery are centered on preclinical 
studies carried out in animals and cannot be readily applied to 
humans [97]. 
The variety of nanoparticles mentioned in the previous sections can 
be targeted via the intranasal route. Liposomes, being organic 
nanoparticles, are readily suited for intranasal delivery as they can 
easily encapsulate the required drug and are available for cellular 
and mucosal uptake [98]. In a study carried on cationic liposomes, it 
was concluded that the nanoparticle showed a greater rate of 
absorption and bioavailability about its negatively charged 
complements [99]. It occurs because the membrane of the mucosa, 
being charged negatively tends to attract to the positively charged 
nanoparticle and subsequently prevents the mucosal cilia clearance 
of the drug [100]. Further, liposomes can be successfully formulated 
as mucosal vaccination since their maintenance in the nasal cavity 
stimulates the immune system causing large amounts of 
immunoglobulin production. Polymeric nanoparticles, especially 
those produced from chitosan forms an appropriate molecule for 
intranasal delivery as they are non-toxic, biodegradable, and can 
open the tight junctions present between the cells of the epithelium 
[101].  
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A new treatment strategy presently under study is the use of 
nanoparticles made of silver through the intranasal route to combat 
coronavirus. Nanoparticles made of silver with a size range of 
approximately 10 nm are applied and the nanoparticles can destroy 
the viruses in the pulmonary epithelium. The silver particle which is 
released from the formulated nanoparticle induces a change in pH 
conditions in the epithelium of the pulmonary system to basic. This 
medium is unfriendly for the survival of the virus and subsequently 
results in the diminished viral count and thus prevents the 
possibility of the virus to transmit from a diseased person to a 
healthy person [102]. The existence of antiviral effects of this 
nanoparticle is caused by the binding of this NP to the virus’s surface 
glycoprotein thus circumventing the fusion of coronavirus to the cell 
structures of the host. The use of silver nanoparticles has resulted in 
a substantial decrease in the production of pro-inflammatory 
cytokines in mice induced with the syncytial virus. These results 
recommend that the use of silver nanoparticles will be efficient 
therapy against the coronavirus. Currently, there are no approved 
trials or animal models induced with coronavirus to conclude the 
use of this NP to treat coronavirus but can certainly be investigated 
for tackling coronavirus [103].  
Nanoparticles made of gold have gained distinct attention in the 
expansion of vaccine invention since they can activate the immune 
system through internalization by the accessory cells. The strategies of 
synthesis, notable progress and future opportunities for using gold NP 
for intranasal vaccinations are being analyzed. Nanoparticles made of 
gold can be effortlessly tailored for mucosal administration and have 
the benefits of easily getting diffused into the lymph nodes with the 
stimulation of killer T-cells mediated immune reactions. With the high 
atomic number, gold NPs can act as greatly constant and biologically 
compatible X-ray contrast agents for imaging purposes particularly in 
computed tomography [104]. VLNPs targeted for intranasal delivery 
against influenza virus revealed that there was an improved immune 
response against this specific virus. Thus it can act as a vaccine that 
can avoid infections by generating T-cells and antibodies [105]. An 
experiment conducted by Kanekiyo M. et al., showed that self-
assembling protein NPs aggravate efficient immune response than 
conventional influenza vaccine after mucosal administration thus 
enabling a potential platform for establishing vaccine development 
against a variety of viruses and other pathogens [106]. The schematic 
illustration of intranasal delivery of different nanoparticles is 
described in fig. 4. 
  
 
Fig. 4: Intranasal delivery of nanoparticles for the purpose of treating SARS-CoV2 infection 
 
Safety and limitations  
NP-based methods of administration have shown enormous 
potential applications, but studies have shown that these methods 
can cause serious damage to the respiratory system and even affect 
lung function. Within NP and related methods, four major 
pathological and biological aspects need to be considered, including 
oxidative stress, genotoxicity, inflammation, and fibrosis [107]. 
Oxidative stress is usually caused by the difference between the 
generation of reactive oxygen species (ROS) and the capability of 
biological mechanisms to eradicate active debris voluntarily.  
Sometimes it can be directly caused by the production of ROS in the 
cell, or it can be caused indirectly by altering mitochondrial 
respiration or by decreasing the antioxidant residue in the cellular 
environment. The oxidative stress barrier can be an important stage 
in initiating a small amount of harmful pathological and biological 
activities in the cell microenvironment [108]. Also, the effect of NP 
on oxidative stress environments in animal models or at the cellular 
level to sense the harmfulness of NPs is usually done by a general 
termination study. The in vivo and in vitro experiments take part in 
considering the mechanism of NPs that cause oxidative stress. For 
instance, researches have shown that after 90 d of continuous 
administration of TiO2 NP in the tube, a large amount of titanium 
dioxide NP (TiO2-NP) accumulated in the lungs of mice. TiO2-NP 
significantly increases the pile-up of ROS levels, inflammation, and 
lipid peroxidation levels and also decreases antioxidant competition 
in the lungs. NPs can produce ROS and subsequently oxidize 
antioxidant residues, which can affect the respiratory system and 
related pathological and biological events, including pneumonia and 
gene-toxicity [109].  
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In some instances, the NPs administered through the nose have been 
observed to cause processes mediated by prolonged or acute 
inflammation, such as the uptake of inflammatory cells and the 
announcement of cytokines [110]. Note that the application of 
graphene oxide (GO) solution directly into the pulmonary system of 
C57BL/6 mice can cause alveolar exudate to cause severe 
pneumonia. NPs have been implicated in eliciting some pro-
inflammatory pathways, along with mitogen-activated protein 
kinase (MAP). Cells treated with NP showed higher levels of the 
transcription factors AP-1 (activator protein 1) and NF-KB (nuclear 
factor activated kappa B cells), which influence the transcription 
process of DNA and cytokine generation and cell survival [111]. 
Primary or secondary genotoxicity is the major problem related to 
NP-mediated delivery mechanisms [112]. Genotoxicity or NP 
residues are directly affected by DNA structure or cell division 
components (like the spindle of microtubule or centromere). Carbon 
nanotubes (CNT) interact easily with components of DNA. This 
indicates that CNT can cause harm to genes in vivo (in an animal 
model) or at the cellular level. Studies have shown that the 
application of many-walled CNTs through the pulmonary route 
induces toxicity to genes by encouraging chronic inflammation, 
resulting in persistent oxidative stress [113]. Fibrosis is considered 
an indicator of the accumulation of inhaled NP in the lungs and 
causes rare pneumonia, such as eosinophilia. In one study, in the 
treated C57BL/6 male mouse model, inhaled single-walled CNTs 
caused multifocal granulomatous pneumonia and fibrosis [114]. 
Several major and important efforts are currently underway to 
develop a scientific research structure for risk management. The U. 
S. National Nanotechnology Program or Research Strategy for 
Environment, Health, and Safety is one of the major structures [115] 
which focus on setting up measuring instruments that can effectively 
determine the physical and chemical properties of nanotechnology-
based or nano-drug delivery systems [116]. Therefore, effective 
management of respiratory infections, diseases, or conditions needs 
to emphasize the above pathological and biological processes to 
define restrictions and improve the protection of NP-centred 
methods [117].  
CONCLUSION 
The severe acute respiratory syndrome called coronavirus 2 caused 
by (SARS-CoV-2) poses a dangerous situation to the world 
population and is the greatest pandemic in recent history. To date, 
the greatly contagious SARS-CoV-2 coronavirus has attacked more 
than 111 million individuals in 216 countries and has caused an 
unparalleled financial disaster due to forced blockages to restrain 
transmission and left the lives of many affected people in danger 
worldwide. Even though the suggested conventional treatment is 
primarily administered intravenously, due to intranasal 
administration, it faces several mucosal challenges. Also, the 
conventional detection methods are based on the detection of 
nucleic acid and contain the following disadvantages like labor-
intensive and low-sensitivity experimental procedures; long time 
between assembling of sample and elucidation of results; greater 
false-negative rate; and absence of specificity leading to 
misdiagnosis of people infected with viruses. Additionally, the use of 
NP-linked delivery systems can provide efficient treatment while 
diminishing the side effects of therapeutic moiety and also 
guarantee that therapeutic residues such as medications, vaccine 
preparations, siRNAs, and peptides reach their targets. Some studies 
have shown that these nanotechnology methods can cause serious 
damage to the airways and even affect lung function. Within NP and 
related methods, four major pathological and biological aspects need 
to be considered, including oxidative stress, genotoxicity, 
inflammation, and fibrosis. Therefore, the fundamental assumption 
is that COVID-19 is a novel disease and may primarily encounter 
some known nanomaterials that have been utilized in preceding 
SARS-CoV or similar viruses.  
FUTURE PERSPECTIVES  
Intranasal administration of biocompatible therapeutic 
nanoparticles may be a promising method to combat this new SARS 
CoV-2, as different methods have previously been used against 
different viral infections (including SARS or MERS coronavirus). 
Therapeutic NPs can improve the distribution of drugs, ensure the 
careful and definite administration of siRNA, effectively administer 
peptide inhibitors, and avoid the virus from entering and trigger the 
immune system of the cell. In the coming years, clinical experiments 
should permit drug therapy combination for tackling the 
coronavirus and also experiments or clinical trials involving models 
of animals must develop beyond usual organisms. Research into 
several promising therapeutic agents for SARS-CoV-2 conveyed via 
intranasal biocompatible drug therapeutic nanoparticles is likely to 
take place shortly which would be more effective than any other 
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